Login to Your Account

Financings Roundup

Friday, February 15, 2013
• Domainex Ltd., of Cambridge, UK, is seeking to raise £1.5 million (US$2.32 million) to advance its kinase-based drug development programs for TBK1/KKe and epigenetics targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription